Investors

Investor Relations

Latest Financial Results

Q1 2023

Quarter Ended Sep 30, 2022

Latest Annual Filing

For Fiscal Year Ending Jun 30, 2022

Email Alerts

Stay informed and receive updates directly to your inbox.

Sign up today

Company Overview

iBio develops next-generation biopharmaceuticals using computational biology and 3D-modeling of subdominant and conformational epitopes, prospectively enabling the discovery of new antibody treatments for hard-to-target cancers and other diseases. iBio’s mission is to decrease drug failures, shorten drug development timelines, and open up new frontiers against the most promising targets. For more information, visit www.ibioinc.com.

Investor Contact Information

Company

iBio Inc.
8800 HSC Pkwy
Bryan, TX 77807
T: 979-446-0027
ir@ibioinc.com

Investor Relations

Stephen Kilmer
T: 646-274-3580
skilmer@ibioinc.com

Market Data copyright © 2022 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.